Golden Agri-Resources Ltd Weak 3Q13 results on low CPO price



Bloomberg | Reuters | POEMS GGR SP | GAGR.SI | GARSA.SG Industry: Plantation

Phillip Securities Research Pte Ltd

Report type: 3Q13 Results

Company Overview

Golden Agri-Resources Ltd (GAR) is the world's second largest palm oil plantation company with plantations located in Indonesia. It has integrated operations focused on the production of palm-based edible oil and fat.

- 9M13 results bel ow expectations
- 0.585 SG cents interim dividend declared
- Maintain Neutral

What is the news?

Golden Agri reported 3Q13 net profit (excluding exceptional items) of US\$36mn (-38.5% QoQ, -59.8% YoY). This brings 9M13 core net profit to US\$203mn (-44.7% YoY), accounting for 54%/58% of PSR/consensus full-year forecast. The group also declared an interim dividend of 0.585 SG cents (vs. 0.6 SG cents last year), given its strong cash position and limited M&A investment opportunities at this point in time.

Figure 1. Results summary

- igure ii iteeaite					
Income statemen	t				
(Extract)	3Q13	3Q12	у-у	2Q13	q-q
(US\$mn)					
Revenue	1,571	1,672	-6.1%	1,682	-6.6%
EBITDA	111	190	-41.8%	140	-21.1%
Net profit	30	86	-64.8%	45	-33.2%
Core net profit	36	91	-59.8%	59	-38.5%


Source: Company, Phillip Securities Research

How do we view this?

The weak performance was due to lower CPO prices, which fell by ~23% YoY during the period, higher operating costs and higher inventory levels. China operation has a slight net loss of US\$2mn in 3Q13, after two quarters of positive trend, indicating that the operating environment in China remains unstable for the group.

Investment Actions?

We trim our FY13E earnings estimates by 19% mainly on the higher operating cost assumptions to reflect weaker 3Q13, but leave our FY14E/15E estimates intact. Our target price remains at S\$0.50, still based on a blend of PE (12.0x FY14E) and DCF valuations. Maintain Neutral.



 Flambo International 				50.0
2. Silchester International				5.0
3. Allianz Asset Management				1.4
Key Financial Summary				
FYE	12/12	12/13F	12/14F	12/15F
Revenue (USD mn)	6,052	5,595	6,529	7,529
Net Profit, adj. (USD mn)	404	307	455	534
EPS, adj. (USD)	0.03	0.02	0.04	0.04
P/E (X),adj.	13.6	17.9	12.1	10.3
BVPS (USD)	0.66	0.68	0.71	0.73
P/B (X)	0.7	0.6	0.6	0.6
DPS (SGD)	0.01	0.01	0.01	0.02

2.1%

1.6%

2.4%

2.8%

Source: Bloomberg, PSR est.

Valuation Method

Div. Yield (%)

50:50 blend of PE-based (12.0X 2014e PE), and DCF valuations

Analyst

Nicholas Ong

nicholasonghg@phillip.com.sg +65 6531 5440



^{*}All multiples & yields based on current market price

Weak 3Q13 results

Golden Agri reported 3Q13 net profit (excluding exceptional items) of US\$36mn (-38.5% QoQ, -59.8% YoY). This brings 9M13 core net profit to US\$203mn (-44.7% YoY), accounting for 54%/58% of PSR/consensus full-year forecast. The weak performance was due to lower CPO prices, which fell by ~23% YoY during the period, higher operating costs and higher inventory levels.

China operation has a slight net loss of US\$2mn in 3Q13, after two quarters of positive trend, indicating that the operating environment in China remains unstable for the group.

The group also declared an interim dividend of 0.585 SG cents (vs. 0.6 SG cents last year), given its strong cash position and limited M&A investment opportunities at this point in time.

Fig 2: Results comparison

Financials (US\$m)	3Q13	3Q12	YoY	2Q13	QoQ
Revenue	1,571	1,672	-6.1%	1,682	-6.6%
- Indonesia	1,221	1,270	-3.8%	1,385	-11.8%
- China	349	403	-13.2%	297	17.6%
EBITDA	111	190	-41.8%	140	-21.1%
- Indonesia	106	210	-49.5%	129	-17.7%
- China	4	-20	-121.7%	11	-60.7%
Profit before tax	42	135	-68.6%	69	-38.6%
Net profit	30	86	-64.8%	45	-33.2%
Core net profit	36	91	-59.8%	59	-38.5%

Source: Company, Phillip Securities Research

Fig 3: Quarterly average selling prices and costs of production (US\$/MT)



Source: Company, Phillip Securities Research

Production growth impacted by biological cycle


3Q13 CPO production rose 16% QoQ (-13% YoY) to 0.56mn tons, as it entered the seasonally higher production period. However, production is still down 13% YoY due to the biological trend following the bumper crop last year. This brings 9M13 production to 1.6mn tons (- 5% YoY). That said, management is confident that production volume will return to the 5-10% range in FY14.

Fig 4: Plantation statistics

Key drivers	3Q13	3Q12	YoY	2Q13	QoQ
FFB output ('000 T)	2,293	2,670	-14.1%	1,967	16.6%
Palm output ('000 T)	694	798	-13.0%	593	17.0%
- CPO	560	647	-13.4%	481	16.4%
- PK	134	151	-11.3%	112	19.6%
FFB yield (T/ha)	5	6	-16.8%	5	16.8%
CPO extraction rate	0	0	-0.1 ppt	0	-0.3 ppt
PK extraction rate	0	0	0.1 ppt	0	0.1 ppt
CPO ASP (US\$/T)	806	993	-18.8%	811	-0.6%
CPO APC (US\$/T)	341	288	18.4%	387	-11.9%

Source: Company, Phillip Securities Research

Fig 5: FFB processed and yield quarterly trend



Source: Company, Phillip Securities Research

Maintain Neutral

We trim our FY13E earnings estimates by 19% mainly on the higher operating cost assumptions to reflect weaker 3Q13, but leave our FY14E/15E estimates intact. Our target price remains at S\$0.50, still based on a blend of PE (12.0x FY14E) and DCF valuations. Maintain Neutral.

Key upside/downside risks: (1) stronger/weaker-thanexpected CPO demand; (2) poor/good weather condition affecting/boosting oilseeds supply; (3) sharp rise/fall in oil prices.

Fig 6: GAR 12-month forward P/E



Source: Company, Phillip Securities Research



FYE Dec	FY11	FY12	FY13F	FY14F	FY15F
Valuation Ratios					
P/E (X), adj.	9.4	13.6	17.9	12.1	10.3
P/B (X)	0.7	0.7	0.6	0.6	0.6
EV/EBITDA (X), adj.	8.3	10.0	12.0	8.9	7.8
Dividend Yield (%)	3.3%	2.1%	1.6%	2.4%	2.8%
Per share data					
EPS, reported (USD)	0.10	0.03	0.02	0.04	0.04
EPS, adj.(USD)	0.05	0.03	0.02	0.04	0.04
DPS (SGcts)	1.84	1.19	0.93	1.37	1.61
BVPS (USD)	0.66	0.66	0.68	0.71	0.73
Growth & Margins (%)					
Growth					
Revenue	69.9%	1.7%	-7.6%	16.7%	15.3%
EBITDA	42.5%	-16.6%	-16.8%	34.2%	15.0%
EBIT	46.7%	-21.3%	-22.5%	38.7%	16.0%
Net Income, adj.	47.6%	-30.9%	-24.0%	48.0%	17.3%
Margins					
EBITDA margin	14.9%	12.3%	11.0%	12.7%	12.6%
EBIT margin	13.3%	10.3%	8.7%	10.3%	10.4%
Net Profit Margin	21.6%	6.9%	5.6%	7.1%	7.2%
Key Ratios					
ROE (%)	7.7%	4.9%	3.6%	5.1%	5.8%
ROA (%)	7.2%	5.0%	3.6%	4.9%	5.5%
Net Debt/(Cash)	809	335	587	668	594
Net Gearing (X)	10.0%	3.9%	6.6%	7.3%	6.2%
Income Statement (USD mn)					
Revenue	5,953	6,052	5,595	6,529	7,529
EBITDA, adj.	889	742	617	828	951
Depreciation & Amortisation	(95)	(116)	(132)	(156)	(172)
EBIT	795	626	485	672	780
Changes in fair value of bio assets	903	49	0	0	0
Finance (Expense)/Income	(53)	(67)	(87)	(93)	(95)
Other items	67	3	35	36	37
Associates & JVs	1	0	0	0	0
Profit Before Tax	1,712	612	433	616	722
Taxation	(428)	(196)	(121)	(154)	(181)
Profit After Tax	1,284	415	312	462	542
Non-controlling Interest	16	6	4	7	8
Net Income, reported	1,268	410	307	455	534
Net Income, adj.	571	404	307	455	534

Source: PSR



FYE Dec	FY11	FY12	FY13F	FY14F	FY15F
Balance Sheet (USD mn)					
PPE	1,759	2,007	2,371	2,621	2,765
Intangibles	117	117	116	116	116
Biological assets	7,804	7,899	7,955	8,011	8,067
Investments	91	531	531	531	531
Others	185	310	309	308	307
Total non-current assets	9,956	10,864	11,282	11,587	11,786
Inventories	751	840	777	906	1,045
Trade Receivables	234	400	504	588	678
Investments	93	126	126	126	126
Cash	277	560	308	227	300
Others	527	496	496	496	496
Total current assets	1,882	2,422	2,210	2,343	2,645
Total Assets	11,837	13,286	13,492	13,930	14,431
Short term loans	422	433	433	433	433
Trade Payables	491	685	671	783	904
Others	231	184	184	184	184
Total current liabilities	1,143	1,302	1,289	1,401	1,521
Long term loans	664	461	461	461	461
Deferred income tax	1,876	1,892	1,892	1,892	1,892
Others	41	1,012	1,012	1,012	1,012
Total non-current liabilities	2,582	3,366	3,366	3,366	3,366
Non-controlling interest	87	92	96	103	110
Shareholder Equity	8,025	8,527	8,742	9,061	9,434
Cashflow Statements (USD mn)					
CFO					
PBT	1,712	612	433	616	722
Adjustments	(759)	155	219	248	266
Cash from ops before WC changes	954	766	652	864	988
WC changes	(115)	(50)	(54)	(102)	(109)
Cash generated from ops	838	717	598	762	879
Taxes paid, net	(142)	(257)	(121)	(154)	(181)
Interest paid,net	(46)	(52)	(87)	(93)	(95)
Cashflow from ops	651	409	390	516	604
CFI					
CAPEX, net	(440)	(390)	(550)	(460)	(370)
Purchase/sale of investments	(85)	(496)	0	0	0
Investments in subs & associates	(2)	0	0	0	0
Others	(35)	(90)	0	0	0
Cashflow from investments	(561)	(976)	(550)	(460)	(370)
CFF					
Share issuance	0	0	0	0	0
Loans, net of repayments	105	(193)	0	0	0
Payment of dividends	(79)	(244)	(92)	(137)	(160)
Others	(44)	1,316	0	0	0
Cashflow from financing	(19)	879	(92)	(137)	(160)
Net change in cash	70	311	(252)	(81)	74
CCE, end	277	560	308	227	300

Source: PSR





PSR Rating System Total Returns Recommendation Rating > +20% Buy +5% to +20% Accumulate 2 -5% to +5% Neutral 3 -5% to -20% Reduce 4 < -20% Sell 5

Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation.



Important Information

This publication is prepared by Phillip Securities Research Pte Ltd., 250 North Bridge Road, #06-00, Raffles City Tower, Singapore 179101 (Registration Number: 198803136N), which is regulated by the Monetary Authority of Singapore ("Phillip Securities Research"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this document by mistake, please delete or destroy it, and notify the sender immediately. Phillip Securities Research shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources, which Phillip Securities Research has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this publication are based on such information and are expressions of belief of the individual author or the indicated source (as applicable) only. Phillip Securities Research has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete, appropriate or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities Research associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, (i) be liable in any manner whatsoever for any consequences (including but not limited to any special, direct, indirect, incliental or consequential losses, loss of profits and damages) of any reliance or usage of this publication or (ii) accept any legal responsibility from any person who receives this publication, even if it has been advised of the possibility of such damages. You must make the final investment decision and accept all responsibility for your investment decision, including, but not limited to your reliance on the information, data and/or other materials presented in this publication.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

Past performance of any product referred to in this publication is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This publication should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this research should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this publication, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this publication.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold a interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this publication. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, which is not reflected in this material, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this material.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.





Section 27 of the Financial Advisers Act (Cap. 110) of Singapore and the MAS Notice on Recommendations on Investment Products (FAA-N01) do not apply in respect of this publication.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

Please contact Phillip Securities Research at [65 65311240] in respect of any matters arising from, or in connection with, this document.

This report is only for the purpose of distribution in Singapore.

Contact Information (Singapore Research Team)

Management

Chan Wai Chee (CEO, Research - Special Opportunities)

Joshua Tan

(Head, Research - Equities & Asset Allocation)

+65 6531 1231

Research Operation Officer Jermaine Tock +65

+65 6531 1240

+65 6531 1249

Macro | Asset Allocation | Equities

Joshua Tan +65 6531 1249

Financials

Nicholas Ong

Ken Ana +65 6531 1793

US Equities

Wong Yong Kai +65 6531 1685

Telecoms

Colin Tan +65 6531 1221

Commodities | Offshore & Marine

+65 6531 5440

Real Estate

Lucas Tan +65 6531 1229

Market Analyst | Equities

Kenneth Koh +65 6531 1791

SINGAPORE

Phillip Securities Pte Ltd

Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101

Tel +65 6533 6001 Fax +65 6535 6631 Website: <u>www.poems.com.sg</u> Kuala Lumpur Tel +603 2162 8841

Fax +603 2166 5099 Website: <u>www.poems.com.my</u>

ANZ Tower Level 23B,

JI Jend Sudirman Kav 33A

Jakarta 10220 - Indonesia

Tel +62-21 5790 0800

Fax +62-21 5790 0809

Contact Information (Regional Member Companies)

MALĂYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II,

No. 12, Jalan Yap Kwan Seng, 50450

HONG KONG Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong Tel +852 2277 6600

Fax +852 2868 5307 Websites: www.phillip.com.hk

JAPAN

Phillip Securities Japan, Ltd.

4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101

Fax +81-3 3666 6090

Website: www.phillip.co.jp

INDONESIA PT Phillip Securities Indonesia Phillip Financial A

CHINA
Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200

Fax +86-21 6351 2940 Website: <u>www.phillip.com.cn</u>

THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921

Website www.phillip.co.th

UNITED STATES
Phillip Futures Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005

INDIA

PhillipCapital (India) Private Limited

No. 1, C- Block, 2nd Floor, Modern Center, Jacob Circle, K. K. Marg, Mahalaxmi Mumbai 400011

Tel: (9122) 2300 2999 Fax: (9122) 6667 9955 Website: <u>www.phillipcapital.in</u>

Website: www.phillip.co.id

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100 Fax +33-1 45636017

Website: www.kingandshaxson.com

AUSTRALIA PhillipCapital

Level 12, 15 William Street, Melbourne, Victoria 3000, Australia Tel +61-03 9629 8288

Fax +61-03 9629 8882 Website: www.phillipcapital.com.au UNITED KINGDOM
King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950

Fax +44-20 7626 1757 Website: www.kingandshaxson.com

SRI LANKA

Asha Phillip Securities Limited

No 321, Lakshmans Building, 2nd floor, Galle Road, Colombo 3, Sri Lanka

Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 Website: www.ashaphillip.net/home.htm

